Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.

@article{Grotti2016PaclitaxelElutingBV,
  title={Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.},
  author={Simone Grotti and Francesco Liistro and Paolo Angioli and Kenneth J Ducci and Giovanni Falsini and Italo Porto and Lucia Ricci and Giorgio Ventoruzzo and Filippo Turini and Guido Bellandi and Leonardo Bolognese},
  journal={Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists},
  year={2016},
  volume={23 1},
  pages={52-7}
}
PURPOSE To report the 3-year safety and effectiveness outcomes from the prospective all-comers DEBATE-ISR study (ClinicalTrials.gov identifier NCT01558531) of symptomatic diabetic patients with femoropopliteal in-stent restenosis (ISR) undergoing treatment with paclitaxel-eluting balloons compared with historical diabetic controls. METHODS From January 2010 to December 2011, 44 consecutive diabetic patients (mean age 74±11 years; 32 men) were treated with drug-eluting balloons (DEBs) and… CONTINUE READING